133 related articles for article (PubMed ID: 32693004)
1. Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer.
Cho H; Wang Z; Levy D
J Theor Biol; 2020 Nov; 505():110403. PubMed ID: 32693004
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
3. A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer.
Wang Z; Cho H; Choyke P; Levy D; Sato N
Bull Math Biol; 2024 Apr; 86(5):57. PubMed ID: 38625492
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
5. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
9. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cancer with Genetically Engineered TCR T Cells.
Smith TW; Nishimura MI
Recent Results Cancer Res; 2020; 214():129-151. PubMed ID: 31473851
[TBL] [Abstract][Full Text] [Related]
11. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Zheng Y; Yang Y; Wu S; Zhu Y; Tang X; Liu X
Bioengineered; 2017 Jul; 8(4):367-373. PubMed ID: 27754760
[TBL] [Abstract][Full Text] [Related]
12. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.
Ochi T; Fujiwara H; Yasukawa M
Expert Opin Biol Ther; 2011 Jun; 11(6):699-713. PubMed ID: 21413911
[TBL] [Abstract][Full Text] [Related]
13. [Cancer immunotherapy using gene-engineered T cells].
Kageyama S
Rinsho Ketsueki; 2018; 59(2):216-224. PubMed ID: 29515077
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
16. The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.
Dass SA; Selva Rajan R; Tye GJ; Balakrishnan V
Hum Vaccin Immunother; 2021 Sep; 17(9):2981-2994. PubMed ID: 33989511
[TBL] [Abstract][Full Text] [Related]
17. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
20. Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer.
Kono K; Ichihara F; Iizuka H; Sekikawa T; Matsumoto Y
Int J Cancer; 1998 Oct; 78(3):301-5. PubMed ID: 9766562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]